The characterization of cellular profiles in the TME of CRC implies the immunomodulatory effect of KRAS mutation, particularly via promotion of inflammation and evasion of the immune response, ultimately leading to tumor progression, invasion, and progression. The gene discussed is KRAS; the disease is colorectal carcinoma.